Transcatheter aortic valve replacement (TAVR), also called transcatheter aortic valve implantation (TAVI), is the implantation of a replacement for the aortic valve through the blood vessels and into the heart, without removing the native valve, used to treat severe aortic stenosis as an alternative to open surgical aortic valve replacement. The first TAVI was performed on April 16, 2002, by Alain Cribier, and the valve can be delivered by several access routes, including transfemoral, transapical, subclavian, direct aortic and transcaval.
Facts
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundationhttps://en.wikipedia.org/wiki/Transcatheter_aortic_valve_replacement, lead sectionQuote, https://en.wikipedia.org/wiki/Transcatheter_aortic_valve_replacement, lead section
Transcatheter aortic valve replacement (TAVR), or transcatheter aortic valve implantation (TAVI), is the implantation of a replacement for the aortic valve through the blood vessels and into the heart, without removing the native valve.
2. Wikipedia: Transcatheter Aortic Valve Replacement Online Reference Encyclopedia Article
WikipediaLead sectionQuote, Lead section
The first TAVI was performed on 16 April 2002 by Alain Cribier.
Frequently Asked Questions
What is transcatheter aortic valve replacement?
Implanting a replacement aortic valve through the blood vessels without open heart surgery, to treat severe aortic stenosis.
Transcatheter aortic valve replacement (TAVR), also called transcatheter aortic valve implantation (TAVI), is the implantation of a replacement for the aortic valve through the blood vessels and into the heart, without removing the native valve. It is an alternative to surgical aortic valve replacement, which requires open heart surgery, and is used to treat severe aortic stenosis. The first TAVI was performed on 16 April 2002 by Alain Cribier.
Who is TAVR recommended for compared with open surgery?
Originally for patients too high risk for open surgery; increasingly offered to intermediate risk patients.
Patients with symptomatic severe aortic stenosis have a mortality rate of approximately 50% at 2 years without intervention. In patients deemed too high risk for open heart surgery, TAVI significantly reduces the rates of death and cardiac symptoms. Until about 2017 it was not routinely recommended for low-risk patients, but it is increasingly offered to intermediate risk patients, based on studies finding it is not inferior to surgical replacement. People who could choose either are likely to choose surgery if younger than 75 and transfemoral TAVI if older than 75, because surgical valves are known to be durable long-term (average durability of 20 years). This record describes what the sources state and is not medical advice.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.
View At A Past Year
Choose a year to see this entry's facts and connections as the atlas records them at that moment: what it held then, what it held instead, and what it had not yet adopted. Choose Present for the current record.